Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Senju Pharmaceutical Co., Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 3 examiners and 3 art units, so the portfolio is distributed across separate examination assignments.
FAY, ZOHREH ALEMZADEH is the busiest examiner, with 1 pending matter. Counsel should use matter-specific preparation and avoid assuming that one examiner’s approach applies across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17796843 | USE OF POLYETHER COMPOUND | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | STEELE, AMBER D | 1658 | §103DP | Final Rejection | 22d | Pending | Nov 12, 2021 |
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | — | Pending | Oct 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSenju Pharmaceutical Co., Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Senju Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
